Literature DB >> 24718382

Impact of the PPARGC1A Gly482Ser polymorphism on left ventricular structural and functional abnormalities in patients with hypertension.

A Rojek1, M Cielecka-Prynda1, M Przewlocka-Kosmala1, L Laczmanski2, A Mysiak1, W Kosmala1.   

Abstract

The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor gamma coactivator-1α (PPARGC1A) has been reported to contribute to the development of left ventricular (LV) hypertrophy. Little is known, however, about its possible impact on cardiac dysfunction. Enhanced myocardial fibrosis accompanying increased LV mass might represent a link with coexisting functional abnormalities. We investigated the association between the PPARGC1A Gly482Ser polymorphism and LV morphology and performance in essential hypertension, with special consideration of fibrosis intensity. A total of 205 hypertensive patients (60±8 years) underwent echocardiography with assessment of cardiac morphology, LV systolic (strain and strain rate) and diastolic function (peak early diastolic mitral flow velocity/peak late diastolic mitral flow velocity (E/A) ratio, peak early diastolic myocardial velocity (Em), and E/e' ratio (where e' is the peak early diastolic mitral annular velocity)), evaluation of serum procollagen type III amino-terminal propeptide (PIIINP) and procollagen type I carboxy-terminal propeptide (PICP)-markers of fibrosis and the PPARGC1A Gly482Ser genotyping. Subjects with the Ser-Ser genotype demonstrated more profound LV hypertrophy and diastolic function impairment, and higher PICP/PIIINP than the Ser-Gly and Gly-Gly groups. In multivariable analysis, the presence of the Ser-Ser allele was an independent correlate of E/e' (β=0.17, P<0.02), Em (β=-0.18, P<0.01) and LV mass index (β=0.28, P<0.001). In conclusion, in hypertensive patients, the PPARGC1A Gly482Ser polymorphism is associated with LV hypertrophy and diastolic dysfunction, with the presence of the Ser-Ser allele promoting these abnormalities. One of the possible mechanisms mediating the adverse effect on diastolic performance might be a relative increase in the anabolism of rigid collagen type I over that of the more elastic collagen type III, as indicated by an increased ratio of PICP to PIIINP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24718382     DOI: 10.1038/jhh.2014.26

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  34 in total

1.  The extracellular matrix is an important source of ultrasound backscatter from myocardium.

Authors:  C S Hall; M J Scott; G M Lanza; J G Miller; S A Wickline
Journal:  J Acoust Soc Am       Date:  2000-01       Impact factor: 1.840

2.  Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study.

Authors:  S R Ommen; R A Nishimura; C P Appleton; F A Miller; J K Oh; M M Redfield; A J Tajik
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

Review 3.  New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.

Authors:  Michael R Zile; Dirk L Brutsaert
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

4.  In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans.

Authors:  E Picano; G Pelosi; M Marzilli; F Lattanzi; A Benassi; L Landini; A L'Abbate
Journal:  Circulation       Date:  1990-01       Impact factor: 29.690

Review 5.  PGC-1 coactivators in cardiac development and disease.

Authors:  Glenn C Rowe; Aihua Jiang; Zolt Arany
Journal:  Circ Res       Date:  2010-10-01       Impact factor: 17.367

6.  Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

Authors:  Richard Müller-Brunotte; Thomas Kahan; Begoña López; Magnus Edner; Arantxa González; Javier Díez; Karin Malmqvist
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

7.  Polymorphisms of the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy.

Authors:  Shuxia Wang; Chunyan Fu; Hu Wang; Yi Shi; Xiqi Xu; Jingzhou Chen; Xiaodong Song; Kai Sun; Jianwei Wang; Xiaohan Fan; Hongjian Wang; Xiaomin Yang; Tujun Huan; Rutai Hui
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

8.  Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men.

Authors:  Hannes Oberkofler; Bertram Hölzl; Harald Esterbauer; Mingqiang Xie; Bernhard Iglseder; Franz Krempler; Bernhard Paulweber; Wolfgang Patsch
Journal:  Hypertension       Date:  2003-02       Impact factor: 10.190

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion.

Authors:  C Ling; S Del Guerra; R Lupi; T Rönn; C Granhall; H Luthman; P Masiello; P Marchetti; L Groop; S Del Prato
Journal:  Diabetologia       Date:  2008-02-13       Impact factor: 10.122

View more
  1 in total

1.  Transcriptomic studies revealed pathophysiological impact of COVID-19 to predominant health conditions.

Authors:  Zulkar Nain; Shital K Barman; Md Moinuddin Sheam; Shifath Bin Syed; Abdus Samad; Julian M W Quinn; Mohammad Minnatul Karim; Mahbubul Kabir Himel; Rajib Kanti Roy; Mohammad Ali Moni; Sudhangshu Kumar Biswas
Journal:  Brief Bioinform       Date:  2021-06-02       Impact factor: 11.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.